Latham & Watkins Advises a Consortium Consisting of Astorg Asset Management, Nordic Capital, Novo Holdings, and Portfolio Company ERT in Completed Merger with Bioclinica

A cross-border team advised on the deal that created the global leader in clinical trial endpoint technology.

April 28, 2021

ERT, a global leader in clinical endpoint data solutions, has announced the close of its merger with Bioclinica, a technological and scientific leader in clinical imaging. This combination creates the global leader in clinical trial endpoint technology and leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with an unrelenting focus on customer service.

Latham & Watkins LLP represented a consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company ERT in the transaction with a corporate deal team led by New York partner David Beller and London and Paris partner Thomas Forschbach.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.